BioXcel Therapeutics, Inc. Restructuring and Related Cost, Number of Positions Eliminated
BioXcel Therapeutics, Inc. (BTAI) had Restructuring and Related Cost, Number of Positions Eliminated of 15 employee as of 2024-09-17, per its 10-K filed 2025-03-28.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Positions Eliminated
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2025-03-28
- 2024-09-17: Restructuring and Related Cost, Number of Positions Eliminated 15.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2024-09-17 | 15.00 employee 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |